Baseline characteristics
| Variable | Male (n=425) | Female (n=249) | P value |
| Age (years) | 71.8±10.5 | 74.9±10.7 | < 0.001 |
| BMI (kg/m2) | 27.8±4.6 | 27.2±5.8 | 0.198 |
| SBP (mmHg) | 133.9±19.4 | 136.9±22.1 | 0.107 |
| Hypertension (n (%)) | 228 (53.6) | 130 (52.2) | 0.718 |
| AF (n (%)) | 47 (11.1) | 37 (14.9) | 0.149 |
| Diabetes (n (%)) | 98 (23.1) | 48 (19.3) | 0.250 |
| Known CAD (n(%)) | 140 (32.9) | 46 (18.5) | < 0.001 |
| Previous PCI (n(%)) | 31 (7.7) | 26 (10.6) | 0.203 |
| Previous CABG (n(%)) | 46 (11.4) | 12 (4.9) | 0.005 |
| ACEI/ARB (n (%)) | 177 (43.5) | 85 (36.8) | 0.099 |
| Beta-blocker (n (%)) | 148 (35.0) | 92 (36.9) | 0.609 |
| Statin (n (%)) | 266 (63.8) | 140 (57.1) | 0.090 |
| BAV (n(%)) | 112 (26.5) | 37 (14.9) | < 0.001 |
| STS mortality score (%) | 1.56 [0.98, 2.55) | 2.30 [1.32, 4.16) | < 0.001 |
| EuroSCORE II (%) | 1.45 [0.91, 3.12) | 2.12 [1.32, 4.16) | < 0.001 |
| NYHA class | |||
| I | 60 (15.6) | 21 (9.3) | 0.020 |
| II | 170 (44.3) | 88 (39.1) | |
| III | 143 (37.2) | 105 (46.7) | |
| IV | 11 (2.9) | 11 (4.9) | |
| Echocardiographic data | |||
| MPG (mmHg) | 48.1±16.4 | 49.2±14.6 | 0.451 |
| PPG (mmHg) | 80.9±24.9 | 83.9±23.1 | 0.157 |
| AVA (cm2) | 0.76±0.23 | 0.66±0.23 | < 0.001 |
| AVAI (cm2/m2) | 0.38±0.11 | 0.38±0.13 | 0.753 |
| Baseline cardiovascular magnetic resonance data | |||
| LVEDVI (mL/m2) | 87.2±26.5 | 79.2±22.1 | < 0.001 |
| LVESVI (mL/m2) | 39.2±24.6 | 33.7±20.1 | 0.002 |
| LVSVI (mL/m2) | 48.0±12.1 | 45.5±10.2 | 0.006 |
| LVEF (%) | 60.0 [51.0, 67.0) | 62.0 [53.0, 69.0) | 0.024 |
| LVMI (g/m2) | 88.6±24.5 | 74.5±21.6 | < 0.001 |
| LV mass/volume | 1.06±0.29 | 0.97±0.25 | < 0.001 |
| RVEDVI (mL/m2) | 72.1±16.8 | 66.1±16.6 | < 0.001 |
| RVEF (%) | 64.0 [57.0, 70.0) | 65.0 [59.0, 73.0) | 0.025 |
| LAVI (mL/m2) | 55.6±21.1 | 58.3±21.9 | 0.127 |
| LGE present (n(%)) | 248 (62.6) | 93 (42.9) | < 0.001 |
| Non-infarct pattern (n(%)) | 157 (39.6) | 65 (30.0) | 0.017 |
| Infarct pattern (n(%)) | 91 (23.0) | 28 (12.9) | 0.003 |
| LGE mass (g) | 1.90 [0.00, 6.51) | 0.00 [0.00, 2.40) | < 0.001 |
| LGE (%LV mass) | 1.12 [0.00, 3.60) | 0.00 [0.00, 1.63) | < 0.001 |
| Intervention type | |||
| SAVR (n(%)) | 282 (66.4) | 117 (47.0) | < 0.001 |
| TAVR (n(%)) | 143 (33.6) | 132 (53.0) | < 0.001 |
P values using independent t-test/Mann-Whitney U test/Χ2 test as appropriate. p<0.05 shown in Bold.
ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; AVA, aorticvalve area; AVAI, aortic valve area index (to BSA); BAV, bicuspidaortic valves; BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass graft; CAD, coronary artery disease; LAVI, left atrial volume index; LGE, late gadolinium enhancement; LV, left ventricle; LVEDVI, LV end-diastolic volume index; LVEF, LV ejection fraction; LVESVI, LV end-systolic volume index; LVMI, LV mass index; LVSVI, LV stroke volume index; MPG, mean pressure gradient; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PPG, peak pressure gradient; RVEDVI, right ventricular (RV) end-diastolic volume index; RVEF, RV ejection fraction; SAVR, surgical aortic valve replacement; SBP, systolic blood pressure; STS, society of thoracic surgeons; TAVR, transcatheter aortic valve replacement.